Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (noted as Galectin Therapeutics Inc. in metadata) for the reporting period of May 13, 2009. The filing details a subsequent closing under a Securities Purchase Agreement originally entered into on February 12, 2009, with 10X Fund, L.P.
Key Financial Metrics
- Gross Proceeds: $900,000 raised from the May 13, 2009 closing.
- Net Proceeds: Approximately $802,000 after deducting an origination fee (3% of gross proceeds) and reimbursement of purchaser expenses.
- Securities Issued:
- 450,000 shares of Series B-2 Preferred Stock (convertible into 1,800,000 shares of Common Stock).
- Class A-1 Warrants exercisable for 1,800,000 shares of Common Stock.
- Class A-2 Warrants exercisable for 1,800,000 shares of Common Stock.
- Class B Warrants exercisable for 3,600,000 shares of Common Stock.
- Debt and Liquidity: The filing does not provide specific data on total debt, cash flow, or liquidity positions beyond the proceeds from this transaction.
Material Changes
The primary material change is the execution of a subsequent closing under the existing Purchase Agreement. This transaction extended the final purchase date for the remaining securities under the agreement to August 11, 2009. The securities were issued as unregistered "restricted securities" under Section 4(2) of the Securities Act and Rule 506 of Regulation D.
Outlook and Risks
Management Commentary: The filing confirms the continuation of the capital raise initiated in February 2009. No specific operational outlook or guidance is provided in this document.
Risks and Contingencies: The issuance of significant warrant coverage (totaling 7,200,000 shares from this closing alone) and convertible preferred stock creates potential for future dilution of existing shareholders. The filing notes that the description of the warrants is qualified by reference to the full text of the warrant forms filed as exhibits.
Investor Verification Checklist
- Verify the total aggregate amount raised under the full Purchase Agreement, including the initial February closing and this May closing.
- Review the specific terms of the Series B-2 Preferred Stock and the warrant exercise prices in the exhibits referenced from the February 18, 2009 filing.
- Confirm the remaining capacity for future closings under the Purchase Agreement before the August 11, 2009 deadline.
- Assess the potential dilution impact of the 1,800,000 convertible shares and 7,200,000 warrant shares issued in this transaction.